Zeenat Qureshi Stroke Institute and Department of Neurology, University of Missouri, Columbia, Missouri, USA.
Institute for Data Science and Informatics, University of Missouri, Columbia, Missouri, USA.
World Neurosurg. 2021 Jul;151:e615-e620. doi: 10.1016/j.wneu.2021.04.089. Epub 2021 Apr 30.
Intracranial hemorrhage (including subarachnoid hemorrhage [SAH]) has been reported in 0.3%-1.2% of patients with coronavirus disease 2019 (COVID-19). However, no study has evaluated the risk of SAH in patients with COVID-19.
We analyzed data from 62 health care facilities using the Cerner de-identified COVID-19 dataset.
There were 86 (0.1%) and 376 (0.2%) patients with SAH among 85,645 patients with COVID-19 and 197,073 patients without COVID-19, respectively. In the multivariate model, there was a lower risk of SAH in patients with COVID-19 (odds ratio 0.5, 95% confidence interval 0.4-0.7, P < 0.0001) after adjusting for sex, age strata, race/ethnicity, hypertension, and nicotine dependence/tobacco use. The proportions of patients who developed pneumonia (58.1% vs. 21.3%, P < 0.0001), acute kidney injury (43% vs. 27.7%, P = 0.0005), septic shock (44.2% vs. 20.7%, P < 0.0001), and respiratory failure (64.0% vs. 39.1%, P < 0.0001) were significantly higher among patients with SAH and COVID-19 compared with patients without COVID-19. The in-hospital mortality among patients with SAH and COVID-19 was significantly higher compared with patients without COVID-19 (31.4% vs. 12.2%, P < 0.0001).
The risk of SAH was not increased in patients with COVID-19. The higher mortality in patients with SAH and COVID-19 compared with patients without COVID-19 is likely mediated by higher frequency of systemic comorbidities.
据报道,在 0.3%-1.2%的 2019 年冠状病毒病(COVID-19)患者中出现了颅内出血(包括蛛网膜下腔出血[SAH])。然而,尚无研究评估 COVID-19 患者中发生 SAH 的风险。
我们使用 Cerner 去识别 COVID-19 数据集分析了来自 62 家医疗机构的数据。
在 85645 例 COVID-19 患者和 197073 例无 COVID-19 的患者中,分别有 86(0.1%)和 376(0.2%)例患者患有 SAH。在多变量模型中,在调整了性别、年龄分层、种族/民族、高血压和尼古丁依赖/吸烟后,COVID-19 患者发生 SAH 的风险较低(比值比 0.5,95%置信区间 0.4-0.7,P<0.0001)。患有肺炎(58.1%比 21.3%,P<0.0001)、急性肾损伤(43%比 27.7%,P=0.0005)、感染性休克(44.2%比 20.7%,P<0.0001)和呼吸衰竭(64.0%比 39.1%,P<0.0001)的患者比例在患有 COVID-19 和 SAH 的患者中明显高于没有 COVID-19 的患者。患有 COVID-19 和 SAH 的患者的院内死亡率明显高于没有 COVID-19 的患者(31.4%比 12.2%,P<0.0001)。
COVID-19 患者的 SAH 风险并未增加。与没有 COVID-19 的患者相比,患有 COVID-19 和 SAH 的患者的死亡率更高,这可能是由于全身性合并症的频率更高所致。